Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Part of paid clinical trials in Bentonville, Arkansas.

Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Study ID
NCT07686263
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Xanomeline/Trospium Chloride — DRUG
    Specified dose on specified days
  • Placebo — DRUG
    Specified dose on specified days

Study Details

The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

Key Dates

Start date
Sep 3, 2026
Status verified
Jun 2026
Primary completion
Mar 3, 2029
Completion
Mar 3, 2029

Study Design

Enrollment
472 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: KarXT
  • Placebo Comparator: Placebo

Primary Outcome Measure

Time From Randomization to the First Relapse Event [ Time Frame: Up to approximately Week 43 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (33)

FacilityCityStateZIPSite coordinators
Local Institution - 0133BentonvilleArkansas72712
Site 0133
Local Institution - 0154BentonvilleArkansas72712
Site 0154
Local Institution - 0021Little RockArkansas72211
Site 0021
Local Institution - 0139Little RockArkansas72204
Site 0139
Local Institution - 0153RogersArkansas72758
Site 0153
Local Institution - 0190AnaheimCalifornia92805
Site 0190
Local Institution - 0040BellflowerCalifornia90706
Site 0040
Local Institution - 0188ChinoCalifornia91710
Site 0188
Local Institution - 0032Culver CityCalifornia90230
Site 0032
Local Institution - 0037Garden GroveCalifornia92845
Site 0037
Local Institution - 0068La HabraCalifornia90631
Site 0068
Local Institution - 0128Lemon GroveCalifornia91945
Site 0128
Local Institution - 0187MontclairCalifornia91763
Site 0187
Local Institution - 0151OrangeCalifornia92868
Site 0151
Local Institution - 0030Pico RiveraCalifornia90660
Site 0030
Local Institution - 0185RedlandsCalifornia92373
Site 0185
Local Institution - 0186RiversideCalifornia92506
Site 0186
Local Institution - 0145HollywoodFlorida33024
Site 0145
Local Institution - 0149HollywoodFlorida33021-
Local Institution - 0075MiamiFlorida33135-
Local Institution - 0054Miami LakesFlorida33016-
Local Institution - 0134Miami SpringsFlorida33166-
Local Institution - 0044West Palm BeachFlorida33407
Site 0044
Local Institution - 0166AtlantaGeorgia30331
Site 0166
Local Institution - 0070Sandy SpringsGeorgia30328
Site 0070
Local Institution - 0189SavannahGeorgia31405
Site 0189
Local Institution - 0056ChicagoIllinois60641
Site 0056
Local Institution - 0067ChicagoIllinois60640-5017
Site 0067
Local Institution - 0023St LouisMissouri63141-
Local Institution - 0135BuffaloNew York14215-
Local Institution - 0183CincinnatiOhio45219
Site 0183
Local Institution - 0047Oklahoma CityOklahoma73112
Site 0047
Local Institution - 0049AustinTexas78754
Site 0049

Find similar trials in Bentonville, AR

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
Local Institution - 0133· Bentonville, ARLocal Institution - 0154· Bentonville, ARLocal Institution - 0021· Little Rock, ARLocal Institution - 0139· Little Rock, ARLocal Institution - 0153· Rogers, ARLocal Institution - 0190· Anaheim, CA

Related Studies